Summary of the pharmacology and clinical status of apixaban, rivaroxaban, and dabigatran
| . | Apixaban . | Rivaroxaban . | Dabigatran . |
|---|---|---|---|
| Brand name | — | Xarelto | Pradaxa |
| Target | Factor Xa | Factor Xa | Factor IIa |
| tmax, h | 1-31 | 2-45 | 1.25-34 |
| Half-life, h | 8-151 | 9-135 | 12-144 |
| Renal excretion | ∼ 25%1 | 66%25 | 80%4 |
| Food effect | Not reported | Delays absorption26 | Delays absorption27 |
| Effect of age | Not reported | Variable28 | None29 |
| Effect of body weight | Not reported | None30 | None31 |
| Clinical status | — | Approved in Canada and Europe for VTE prevention after orthopedic surgery | Approved in Canada and Europe for VTE prevention after orthopedic surgery |
| . | Apixaban . | Rivaroxaban . | Dabigatran . |
|---|---|---|---|
| Brand name | — | Xarelto | Pradaxa |
| Target | Factor Xa | Factor Xa | Factor IIa |
| tmax, h | 1-31 | 2-45 | 1.25-34 |
| Half-life, h | 8-151 | 9-135 | 12-144 |
| Renal excretion | ∼ 25%1 | 66%25 | 80%4 |
| Food effect | Not reported | Delays absorption26 | Delays absorption27 |
| Effect of age | Not reported | Variable28 | None29 |
| Effect of body weight | Not reported | None30 | None31 |
| Clinical status | — | Approved in Canada and Europe for VTE prevention after orthopedic surgery | Approved in Canada and Europe for VTE prevention after orthopedic surgery |
— indicates not applicable; and tmax, time to maximum plasma concentration.